FTC settles case against Shkreli’s Vyera 

The Federal Trade Commission Tuesday filed a proposed settlement of an antitrust suit against Vyera and its parent company involving allegations that they illegally monopolized U.S. sales of Daraprim, increased the price by 4,000%, and took steps to prevent sales and distribution of lower cost generic versions of pyrimethamine.

The settlement would bar Vyera Pharmaceuticals LLC employee Kevin Mulleady from working in the pharmaceutical industry and force the company to pay $10 million to individuals who were harmed by its actions and potentially an additional $30 million if the company’s financial condition improves. ...